GlassScriptPhysician profile
Viktoriya Rudnik
NPI 1366882466
$6,390.31
in general payments reported to CMS, 2019-2025
28 companies · $2,573 in 2025
The $2,573 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $368 · 2021: $229 · 2022: $605 · 2023: $665 · 2024: $1,754 · 2025: $2,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,991.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,023.02 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Visioneering Technologies, INC. | $947.91 | 2024-2025 | |
| Harrow Eye, LLC | $600.85 | 2024-2025 | Vevye, Ilevro |
| Tarsus Pharmaceuticals, INC. | $569.91 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $450.11 | 2022-2025 | Rocklatan, Simbrinza |
| Novartis Pharmaceuticals Corporation | $432.49 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $240.23 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $217.88 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Coopervision INC. | $216.38 | 2020-2024 | Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $204.57 | 2022-2024 | |
| Sight Sciences, INC. | $178.71 | 2019-2023 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.35 | 2019-2021 | |
| Abbvie INC. | $156.96 | 2022-2025 | |
| Dompe US, INC. | $148.70 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $132.52 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $132.43 | 2023-2025 | Iyuzeh |
| Astellas Pharma US INC | $112.19 | 2024-2025 | Izervay |
| Rxsight INC | $93.75 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Ivantis, INC | $71.43 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $57.42 | 2023 | Eylea Hd |
| Shire North American Group INC | $46.10 | 2019 | |
| Aerie Pharmaceuticals, INC. | $42.91 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $35.99 | 2021 | |
| Mallinckrodt Hospital Products INC. | $30.92 | 2025 | Acthar |
| Horizon Therapeutics Plc | $23.89 | 2023 | Tepezza |
| Amgen INC. | $21.93 | 2024 | Tepezza |
| Akorn, INC. | $19.93 | 2020 | |
| Kala Pharmaceuticals, INC. | $16.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viktoriya Rudnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.